Skip to main content

Table 1 Demographics of the study population

From: Clopidogrel versus ticagrelor in the treatment of Chinese patients undergoing percutaneous coronary intervention: effects on platelet function assessed by platelet function tests and mean platelet volume

Variables

Aspirin + clopidogrel group

(n = 46)

Aspirin + ticagrelor group

(n = 66)

P

Age, yrs.

58.1 ± 9.1

56.3 ± 11.6

0.401

Male, n (%)

36(78.3)

55(83.3)

0.499

BMI, kg/m2

25.9 ± 3.3

25.9 ± 3.2

0.963

LVEF, %

63.0(60.0, 66.0)

60.0(52.8, 65.0)

< 0.001

Risk factors

 Hypertension, n (%)

33(71.7)

31(47.0)

0.009

 Diabetes, n (%)

9(19.6)

26(39.4)

0.026

 Hyperlipidemia, n (%)

43(93.5)

58(89.2)

0.441

Past history

 Previous PCI, n (%)

9(19.6)

28(42.4)

0.011

 Previous MI, n (%)

17(37.0)

56(84.8)

< 0.001

 Previous stroke, n (%)

10(22.2)

4(6.1)

0.012

Medications

 Statins, n (%)

46(100.0)

66(100.0)

1.000

 ACEI, n (%)

11(24.4)

29(46.0)

0.022

 ARB, n (%)

8(18.2)

7(11.1)

0.300

 β-blocker, n (%)

38(84.4)

60(93.8)

0.112

Laboratory

 Hemoglobin, g/L

147.7 ± 14.0

143.5 ± 12.4

0.095

 LDL-C, mmol/L

2.0(1.7, 2.8)

2.2(1.5, 2.7)

0.708

 HsCRP, mg/L

1.1(0.5, 3.0)

2.6(1.2, 7.2)

0.006

 AST, U/L

22.0(19.0, 27.5)

27.0(20.0, 85.0)

0.007

 ALT, U/L

27.0(17.0, 39.2)

32.5(22.8, 52.5)

0.022

 Platelet, 109 cells/L

223.1 ± 60.2

244.7 ± 69.7

0.091

 MPV, fL

11.4 ± 1.4

10.2 ± 0.9

< 0.001

  1. Values are mean ± SD if the distribution is normal; median (interquartile range) if skewed; number, n (proportions, %) for categorical variables
  2. ACEI Angiotensin converting enzyme inhibitor, ALT Alanine transaminase, AST Aspartate transaminase, ARB Angiotensin receptor blocker, BMI Body mass index, CABG Coronary artery bypass graft, hsCRP highly sensitive C-reactive protein, LDL-C Low-density lipoprotein cholesterol, LVEF Left ventricular ejection fraction, MI Myocardial infarction, MPV Mean platelet volume, PCI Percutaneous coronary intervention